Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26045340

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 Jul
First author
Thatcher N

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):738-9. doi: 10.1016/S1470-2045(15)00020-0.
    note
    Source null
    related pmid
    26045341
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Aug;12(8):436. doi: 10.1038/nrclinonc.2015.110.
    note
    Source null
    related pmid
    26122186
    relationship
    Comment in

Authors and identifiers

  1. name
    Thatcher N
    type
    Author
  2. name
    Hirsch FR
    type
    Author
  3. name
    Luft AV
    type
    Author
  4. name
    Szczesna A
    type
    Author
  5. name
    Ciuleanu TE
    type
    Author
  6. name
    Dediu M
    type
    Author
  7. name
    Ramlau R
    type
    Author
  8. name
    Galiulin RK
    type
    Author
  9. name
    Bálint B
    type
    Author
  10. name
    Losonczy G
    type
    Author
  11. name
    Kazarnowicz A
    type
    Author
  12. name
    Park K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Thatcher N
    type
    Author
  2. name
    Hirsch FR
    type
    Author
  3. name
    Luft AV
    type
    Author
  4. name
    Szczesna A
    type
    Author
  5. name
    Ciuleanu TE
    type
    Author
  6. name
    Dediu M
    type
    Author
  7. name
    Ramlau R
    type
    Author
  8. name
    Galiulin RK
    type
    Author
  9. name
    Bálint B
    type
    Author
  10. name
    Losonczy G
    type
    Author
  11. name
    Kazarnowicz A
    type
    Author
  12. name
    Park K
    type
    Author
bibliography ids
  1. nci-bib-9bf18521b1695327c970b1d6
book metadata
content sha256
e29164794205b3bed5eec2acb5eddcc99fda45906260b938725786105094e934
document type
citation
dois
  1. 10.1016/S1470-2045(15)00021-2
electronic publication date
display
2015 Jun 1
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26045340
immutable id
pubmed:26045340@e29164794205b3bed5eec2acb5eddcc99fda45906260b938725786105094e934
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
763-74
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 Jul;16(7):738-9. doi: 10.1016/S1470-2045(15)00020-0.
    note
    Source null
    related pmid
    26045341
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2015 Aug;12(8):436. doi: 10.1038/nrclinonc.2015.110.
    note
    Source null
    related pmid
    26122186
    relationship
    Comment in
outcomes validated
false
pmid
26045340
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
4fde51a1dcc2cfa410f42fdb1c8ad47daa1c42527f381d1ab440f70e380711d1
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 Jul
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26045340/
title
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Preserved source evidence · Not medical advice